BCAN’s Young Investigator Awards support outstanding early-career scientists and clinical cancer researchers with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer. Applicants may be working in basic, translational, clinical, epidemiologic, bioengineering sciences or any other field, but projects must be specific to bladder cancer and/or upper tract urothelial carcinoma, and the applicant’s research environment must be capable of supporting transformational bladder cancer research.
Applicants must have a mentor within or approved by the sponsoring institution that will assume responsibility for the overall conduct of the project and provide guidance and protected research time.
What is the Patient-Centered Clinical Research Young Investigator Award?
The Patient-Centered Clinical Research Young Investigator Award (PCC-YIA) supports early-career scientists and clinical cancer researchers investigating transformational patient-oriented clinical bladder cancer and/or upper tract urothelial cancer research (e.g. studies of shared decision making, access to care, quality of care, quality of life, health disparities, comparative effectiveness research, patient-centered outcomes research, and survivorship).
Applicants must have a mentor within or approved by the sponsoring institution that will assume responsibility for the overall conduct of the project and provide guidance and protected research time.
Project Period: 1 year
Total Funding: $75,000; Indirect costs are not allowable
Guidelines for Young Investigator Award
Guidelines for Patient-Centered Clinical Research
MEET OUR FUNDED YOUNG INVESTIGATORS
Contact us at grants@bcan.org.
More information
Learn more about the Bladder Cancer Advocacy Network’s research grant program as well as additional funding opportunities.
Updates on advanced bladder cancer treatment
October 30th 2023"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.